CMC-544 compared to Investigator Choice in Non-Hodgkin's Lymphoma

• Research type

  Research Study

• Full title

  An Open-label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab Compared to a Defined Investigator’s Choice Therapy in Subjects With Relapsed or Refractory, CD22- Positive, Follicular B-Cell Non-Hodgkin’s Lymphoma 3129K4-3301-WW

• Contact name

  Mikayala King

• Contact email

  mikayala.king@uhs.nhs.uk

• Sponsor organisation

  Wyeth Research Division of Wyeth Pharmaceuticals France

• Eudract number

  2007-000219-27

• Clinicaltrials.gov Identifier

  NCT00562965

• REC name

  South Central - Hampshire B Research Ethics Committee

• REC reference

  08/H0504/67

• Date of REC Opinion

  20 Nov 2008

• REC opinion

  Further Information Favourable Opinion